| Status | Topic selection |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Decision makers have concluded that the clear rationale to not evaluate your product is due to a clinical guideline (CG150) being available that already which includes a recommendation for the use of combination therapy with an oral triptan and an NSAID for the acute treatment of migraine. Therefore, a TA would not add any further value. |
| ID number | 12055 |
Project Team
| Project lead | Danielle Lees |
Email enquiries
- If you have any queries please email topic.selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 September 2024 | Topic selection |
| 10 September 2024 | Topic selection |
For further information on how we select topics for development, please see our page about topic selection